Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 32.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 138,028 shares of the company's stock after acquiring an additional 33,770 shares during the period. Federated Hermes Inc. owned approximately 0.25% of Arvinas worth $5,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in Arvinas by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company's stock worth $27,000 after buying an additional 674 shares in the last quarter. Sectoral Asset Management Inc. lifted its position in Arvinas by 13.5% during the 3rd quarter. Sectoral Asset Management Inc. now owns 7,010 shares of the company's stock worth $138,000 after buying an additional 835 shares in the last quarter. Swiss National Bank lifted its position in Arvinas by 1.2% during the 3rd quarter. Swiss National Bank now owns 99,700 shares of the company's stock worth $1,958,000 after buying an additional 1,200 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in Arvinas by 7.3% during the 4th quarter. Harbor Capital Advisors Inc. now owns 18,167 shares of the company's stock worth $748,000 after buying an additional 1,239 shares in the last quarter. Finally, BluePath Capital Management LLC bought a new stake in Arvinas during the 3rd quarter worth about $28,000. Institutional investors own 95.19% of the company's stock.

Insider Buying and Selling

In other news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ronald Peck sold 1,699 shares of the business's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the transaction, the insider now owns 67,516 shares in the company, valued at $3,176,627.80. The disclosure for this sale can be found here. Insiders sold 8,597 shares of company stock valued at $404,489 over the last quarter. Insiders own 5.23% of the company's stock.

Arvinas Trading Up 2.4 %

Arvinas stock traded up $0.77 during mid-day trading on Friday, reaching $32.37. The company had a trading volume of 778,717 shares, compared to its average volume of 723,138. Arvinas, Inc. has a fifty-two week low of $13.57 and a fifty-two week high of $53.08. The company has a market cap of $2.21 billion, a P/E ratio of -4.93 and a beta of 1.94. The business has a fifty day simple moving average of $41.93 and a 200 day simple moving average of $34.46.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.15) by ($1.38). Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The company had revenue of ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. During the same quarter in the prior year, the business earned ($1.56) EPS. Research analysts forecast that Arvinas, Inc. will post -5.02 EPS for the current year.

Analysts Set New Price Targets

ARVN has been the topic of a number of research analyst reports. BMO Capital Markets upped their target price on shares of Arvinas from $89.00 to $90.00 and gave the company an "outperform" rating in a report on Wednesday, February 28th. Truist Financial reaffirmed a "buy" rating and issued a $65.00 target price on shares of Arvinas in a report on Monday, March 25th. Leerink Partnrs reaffirmed an "outperform" rating on shares of Arvinas in a report on Thursday, February 22nd. Barclays increased their price target on shares of Arvinas from $26.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Finally, Citigroup cut shares of Arvinas from a "buy" rating to a "neutral" rating and increased their price target for the company from $36.00 to $55.00 in a report on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Arvinas presently has an average rating of "Moderate Buy" and a consensus target price of $59.73.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.